Articles tagged with Cancer Medication
A new study found that most parents of children are dissatisfied with the way clinicians communicate about suspected adverse drug reactions. Parents were unsure whether a child's reaction to a drug affected future use of the medicine, but those whose children had cancer expressed confidence in their clinicians' explanations.
Two USC research groups awarded $2.38M and $220K to study epigenetic drivers of cancer and how NSAIDs prevent colorectal cancer. A third group aims to develop new drugs to inhibit 'undruggable' target molecules.
A recent study from York University found that drugs approved through Health Canada's accelerated review process are more likely to be withdrawn or earn serious safety warnings than those undergoing standard reviews. This is due to the faster review process potentially missing serious safety issues.
Researchers have designed a blood test that can detect aggressive prostate cancers by analyzing the pattern of gene activity in blood cells. The test, which reads genetic changes like a barcode, can accurately identify patients with advanced prostate cancers and predict their survival time.
Research from UAlberta finds that overweight and obese children aged 12-19 are 59% more likely to take prescription medication. This trend contributes to higher health-care costs for treating childhood obesity.
The CU Cancer Center is conducting a Phase I clinical trial of OMP-54F28, a drug that targets cancer stem cells and the Wnt signaling pathway. The trial aims to assess the safety and efficacy of the agent in patients with advanced solid tumor cancers.
Researchers discovered microbial-dependent mechanisms that fuel cancer growth, exploiting immune cells and disrupting tissue homeostasis. Inhibiting inflammation may reduce cancer risk by up to 45%.
Scientists at USC have discovered a new type of drug that works by targeting Protein Disulfide Isomerase (PDI) in ovarian cancer cells. The drug, PACMA31, has shown promise in reducing the number of doses needed and making it effective for patients with resistant cancer.
Researchers at Wake Forest University have designed a targeted therapy that delivers a sneak attack on breast cancer cells, similar to a Trojan horse. The new platinum-based molecule has shown promising results in treating non-small cell lung cancer and pancreatic cancer, with potential applications for breast cancer treatment.
Evidence suggests aspirin may lower colorectal cancer risk by 24% and mortality rates by 35%, but concerns remain about side effects. The ESMO Congress debates whether aspirin should be used for chemoprevention of colorectal adenoma/cancer.
Researchers at the University of Texas Health Science Center San Antonio have discovered a potential cure for triple-negative breast cancer. They found that microRNAs can sensitize drug-resistant tumors to chemotherapy drugs like paclitaxel, reducing side effects and improving treatment outcomes.
Cancer drugs are administered sequentially or in combination, creating a virtual monopoly for each drug. Value-based pricing is a potential solution to address the high cost of cancer therapy.
Researchers from the Universities of Sheffield and Cologne have identified Aurora kinase as a critical protein in Small Cell Lung Cancer (SCLC) survival. Targeted therapeutic strategies focusing on Aurora kinase inhibitors show promise, particularly for patients with MYC gene amplification.
Several new first-in-human studies for drugs targeting a range of cancers have shown promising results, including the development of MEK-, MET- and HSP90 inhibitors as well as immunotherapeutic strategies. Studies have demonstrated significant activity in ALK-positive lung cancer resistant to crizotinib and other targeted therapies.
A landmark survey reveals that many countries fail to provide essential opioid medications for cancer pain relief, leaving hundreds of millions of patients suffering. The study's findings highlight the need to reformulate national plans and repeal excessive restrictions on cancer care.
A phase I/II study found that combining dabrafenib and trametinib delayed the development of treatment resistance in melanoma patients. The combination was at least twice as effective as BRAF inhibition alone, with significant delays in resistance emergence.
Phase I and II trials of combining drugs to treat melanoma, including dabrafenib and trametinib, demonstrate a clinically meaningful improvement in progression-free survival, response rate, and duration of response. These studies suggest the potential for new drug combinations to delay resistance to BRAF inhibitors.
Researchers have found that elevated expression of c-Myc amplifies the activity of all expressed genes in tumor cells, leading to increased transcription and proliferation. This discovery provides a simple explanation for how a single protein can have a profound effect in many types of cancer.
UNM Cancer Center researchers have identified R-ketorolac as a potential treatment for ovarian cancer cells, using flow cytometry and computer modeling to target specific GTPases. Initial animal studies show promising results in controlling tumor growth.
The UCSD-based Chronic Lymphocytic Leukemia Research Consortium will continue its critical work on understanding CLL's development and progression. The five-year grant will enable researchers to develop new drugs and treatments for the disease, which affects over 15,000 people annually in the US.
Researchers at Duke University Medical Center developed a policy to manage drug shortages in hospitals, prioritizing patients based on clinical need and effectiveness. The policy establishes clear rules for apportioning scarce drugs, ensuring fairness and minimizing waste.
Researchers at Northwestern University have identified two promising therapies to treat AMKL: alisertib and dimethylfasudil. Alisertib targets Aurora A kinase and shows promise in mouse models, while dimethylfasudil boosts mature bone marrow cells and inhibits malignant ones.
Researchers Stuart Aaronson and Ross Cagan received a $351,713 grant from the National Cancer Institute to investigate signaling pathways responsible for Wnt oncogene addiction. They aim to discover potent drugs that can disrupt this addiction in tumor cells, increasing the efficacy of therapy for Wnt-activated human cancers.
A new study found that split-dose preparation significantly improved polyp detection rates and adenoma detection rates, as well as the quality of bowel prep and colonoscopy completion rates. This approach involves dividing the preparation into two doses, taken before and after the procedure, to improve patient compliance and efficacy.
Researchers will examine cancer cell drug resistance and focus on prevention strategies using breast cancer as a proof-of-concept model. The goal is to minimize the probability of drug-resistant cancer cells emerging, which are a major cause of current cancer treatment failure.
Researchers at Weill Cornell Medical College reveal that taxanes work by stopping protein movement in cancer cells, not just cell division. This understanding could lead to novel therapies and improved treatment outcomes for prostate cancer patients.
A phase 3 trial confirms abiraterone acetate's efficacy in extending average survival time to 15.8 months for castration-resistant prostate cancer patients. The treatment, which blocks testosterone production, also has a good safety profile.
A large Taiwanese study of 35,871 patients with newly diagnosed shingles found no increased risk of cancer. The study suggests that enhanced surveillance for cancer after a shingles diagnosis is unnecessary, according to the authors.
Researchers at MD Anderson Cancer Center have identified a promising therapy for NRAS-mutant melanoma patients. By combining two drugs that inhibit proteins Mek and Cdk4, scientists found that the combination shrinks tumors in genetically engineered mouse models.
A whole-genome scan can help identify large-scale chromosomal damage, enabling doctors to choose the most effective treatment option for children with neuroblastoma. The study recommends that all children diagnosed with neuroblastoma worldwide have a whole-genome scan as part of their treatment.
Researchers at URMC found that defective cholesterol exportation appears to be a key component in various cancers. They demonstrated that re-establishing the cholesterol export function in human colon cancer cells inhibited tumor growth.
Scientists at Karolinska Institutet developed a new technique using under-twisted DNA origami to deliver cancer drugs, such as doxorubicin, directly to tumor cells while minimizing harm to surrounding healthy tissue. This approach allows for slower release of the drug, enabling more effective treatment at lower concentrations.
Researchers at UNC Health Care have discovered a prime suspect for new cancer drug development: the CIB1 protein. Decreasing CIB1 in cancer cells causes cell death, but the exact mechanism was unknown until now.
A new study found that smokers with lung cancer have 10 times more genetic mutations than those who have never smoked. The researchers identified over 3,700 mutations across all patients and found at least one mutated gene in each non-smoking patient that can be targeted with existing drugs.
Researchers have created a new type of miniature pump activated by body heat that could be used in drug-delivery patches powered by fermentation. The micropump utilizes temperature-dependent gas generation through yeast fermentation to push against a membrane, pumping for several hours.
A new study shows that combining a protein inhibitor with VEGF targeting could more effectively treat diseases by shutting down abnormal blood vessel growth. This approach may also lead to improved treatments for eye diseases and autoimmune disorders.
A new study found a potential link between recreational marijuana use and an increased risk of developing subtypes of testicular cancer. The research suggests that marijuana may trigger carcinogenesis in the testis through the endocannabinoid system.
The public favors treating patients with serious conditions, including cancer, if it reduces burden on carers or offers substantial health benefits. However, the majority oppose a ring-fenced budget for cancer drugs, which would prioritize cancer treatments over other equally serious conditions.
A genome-wide scan of small cell lung cancers reveals an association between SOX2 gene amplification and aggressive disease. Overproduction of SOX2 proteins may ignite or sustain abnormal cell growth in the lung.
Researchers at Karolinska Institutet in Sweden have discovered that sorafenib can effectively treat multiple myeloma by inducing cell death in human myeloma cell lines. The study found that the drug also prevented or delayed disease progression in live mice, supporting its use as a treatment for this blood cancer.
Stephen Byers, a Georgetown Lombardi Comprehensive Cancer Center professor, has been awarded a $2.5 million NCI grant to investigate how certain drugs may prevent cancer. The research aims to understand the mechanism of action of anti-inflammatory drugs that have shown promise in preventing cancer and rheumatoid arthritis.
Researchers analyzed data from 29,423 adult patients and found no statistically significant increased risk of any type of cancer in those treated with biologic response modifiers. This study provides reassuring information for patients considering these therapies for their disease.
Researchers explored the effectiveness of resveratrol in preventing head and neck cancer in Fanconi anemia patients, a rare genetic disorder affecting DNA repair. The study found that resveratrol may eliminate cancer cells in these patients by making them sensitive to certain drugs.
Researchers suggest a 'cyber war' on cancer by breaking the code of cancer cells' social behavior, similar to bacterial colonies. This approach could help prevent dormancy and reawaken cells for targeted chemotherapy attacks.
Researchers at University of Missouri have developed a new cancer drug with exceptional potency, outperforming current treatments by 10 times. The carborane-based drug efficiently targets energy production in cancer cells, minimizing side effects and increasing therapy effectiveness.
Researchers used an experimental cancer drug to treat abnormal brain cell growth in mice with neurofibromatosis 1. The study showed that early treatment can prevent learning disabilities in these children by promoting normal neural stem cell development.
A study published in the Journal of Thoracic Oncology found that patients with low thymidylate synthase (TS) levels and high fibroblast growth factor stimulator (FPGS) levels respond better to pemetrexed treatment. This combination predicts longer survival durations.
A Phase I/II trial tests the safety and efficacy of PR610 in patients with advanced cancer. The study aims to deliver a targeted approach, activating the compound in tissues with low oxygen levels characteristic of many cancers.
A multicenter study found that taking aspirin is associated with a lower risk of death from prostate cancer, especially in high-risk disease. The study analyzed data from almost 6,000 men with prostate cancer treated with surgery or radiotherapy, and the results showed a significant reduction in mortality rates and cancer recurrence.
A recent University of Colorado Cancer Center case study found a patient with ALK+ lung cancer who tested negative for the EML4-ALK fusion gene using the FDA-approved FISH assay, yet showed dramatic response to crizotinib. Next-gen sequencing revealed genetic shards that may have avoided detection by the test.
A drug trial found that TAS-102 improved survival time, reduced risk of death, and controlled disease progression in patients with advanced, inoperable colorectal cancer. Patients treated with TAS-102 had a median overall survival of 9 months, compared to 6.6 months for the placebo group.
Researchers are developing drugs that exploit the body's natural immune system to fight diseases. These 'antibody-recruiting molecules' can be taken orally and induce a patient's own antibodies to fight disease.
A study published in Cancer Research identified a gene that disrupts the inflammatory process implicated in liver cancer. Laboratory mice bred without this gene lacked pro-inflammatory protein TREM-1 and protected themselves from developing liver cancer after exposure to carcinogens.
Researchers at Moffitt Cancer Center report on immune-related adverse events associated with ipilimumab and tremelimumab, two anti-CTLA-4 antibodies used in treating metastatic melanoma. The study highlights the importance of early recognition and management of these side effects to improve treatment outcomes.
A University of Rochester Medical Center study challenges traditional treatment guidelines for early-stage follicular lymphoma, concluding that six different therapies can bring remission. Careful patient staging is key to predicting prognosis and superior progression-free survival.
Scientists have discovered that thiabendazole, a generic antifungal drug, can decrease blood vessel growth in tumors, starving them of nutrients. The study also found that the drug slows tumor growth, suggesting it could be used in combination with other chemotherapies.
Scientists have developed a new material to restore lost flexibility in human vocal cords, which can help alleviate voice loss due to aging, disease, or medical procedures. The material, called polyethylene glycol 30 (PEG30), is flexible and can vibrate like human vocal cords.
A new technology developed by scientists can authenticate drugs in minutes, helping patients in developing countries receive real treatments instead of counterfeit ones. The device uses mass spectrometry and can distinguish between genuine and fake medications.
A new study published in the journal Stroke found that black stroke survivors had higher blood pressure a year after their initial stroke. High blood pressure is a significant risk factor for having another stroke, and controlling it can cut the risk in half.
Computer simulations shed light on the dynamic structure of the LSD1/CoREST protein complex, a major target for therapies. The study reveals that binding to histone H3 triggers significant changes in shape, which may help develop epigenetic drugs that reprogram cancer cells.